Acetazolamide: A second wind for a respiratory stimulant in the intensive care unit?

Critical Care

Volumn 16, Issue 4, 2012, Pages

  Heming, Nicholas ^a   Urien, Saïk ^b   Faisy, Christophe ^a  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; CORTICOSTEROID; FUROSEMIDE; RESPIRATORY STIMULANT AGENT; CARBONATE DEHYDRATASE INHIBITOR;

ARTERIAL BLOOD; ARTERIAL GAS; ARTICLE; ARTIFICIAL VENTILATION; CATALYSIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CRITICAL ILLNESS; DIABETES MELLITUS; DISEASE EXACERBATION; DISORDERS OF ACID BASE BALANCE; GLAUCOMA; HEPATIC ENCEPHALOPATHY; HUMAN; HYPERCAPNIA; HYPERTENSION; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPHOSPHATEMIA; IATROGENIC DISEASE; INTENSIVE CARE UNIT; LIVER CIRRHOSIS; LUNG MINUTE VOLUME; METABOLIC ALKALOSIS; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY ACIDOSIS; RISK FACTOR; ADVERSE EFFECTS; ALKALOSIS; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ACETAZOLAMIDE; ALKALOSIS; CARBONIC ANHYDRASE INHIBITORS; HUMANS; INTENSIVE CARE UNITS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATION, ARTIFICIAL;

EID: 84864799722     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc11323     Document Type: Article

References (52)

1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.
2. Gunen H, Hacievliyagil SS, Kosar F, Mutlu LC, Gulbas G, Pehlivan E, Sahin I, Kizkin O. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005, 26:234-241. 10.1183/09031936.05.00024804, 16055870.
3. Moran JL, Green JV, Homan SD, Leeson RJ, Leppard PI. Acute exacerbations of chronic obstructive pulmonary disease and mechanical ventilation: a reevaluation. Crit Care Med 1998, 26:71-78. 10.1097/00003246-199801000-00019, 9428546.
4. Seneff MG, Wagner DP, Wagner RP, Zimmerman JE, Knaus WA. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995, 274:1852-1857. 10.1001/jama.1995.03530230038027, 7500534.
5. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003, 326:185. 10.1136/bmj.326.7382.185, 140272, 12543832.
6. Rivera-Fernandez R, Navarrete-Navarro P, Fernandez-Mondejar E, Rodriguez-Elvira M, Guerrero-Lopez F, Vazquez-Mata G. Six-year mortality and quality of life in critically ill patients with chronic obstructive pulmonary disease. Crit Care Med 2006, 34:2317-2324. 10.1097/01.CCM.0000233859.01815.38, 16849998.
7. Gursel G. Determinants of the length of mechanical ventilation in patients with COPD in the intensive care unit. Respiration 2005, 72:61-67. 10.1159/000083402, 15753636.
8. Nevins ML, Epstein SK. Predictors of outcome for patients with COPD requiring invasive mechanical ventilation. Chest 2001, 119:1840-1849. 10.1378/chest.119.6.1840, 11399713.
9. Menzies R, Gibbons W, Goldberg P. Determinants of weaning and survival among patients with COPD who require mechanical ventilation for acute respiratory failure. Chest 1989, 95:398-405. 10.1378/chest.95.2.398, 2914493.
10. Quinnell TG, Pilsworth S, Shneerson JM, Smith IE. Prolonged invasive ventilation following acute ventilatory failure in COPD: weaning results, survival, and the role of noninvasive ventilation. Chest 2006, 129:133-139. 10.1378/chest.129.1.133, 16424423.
11. Webster NR, Kulkarni V. Metabolic alkalosis in the critically ill. Crit Rev Clin Lab Sci 1999, 36:497-510. 10.1080/10408369991239286, 10560889.
12. Gallagher TJ. Metabolic alkalosis complicating weaning from mechanical ventilation. South Med J 1979, 72:786-787. 10.1097/00007611-197907000-00007, 377506.
13. Gluck SL. Acid-base. Lancet 1998, 352:474-479. 10.1016/S0140-6736(98)03087-6, 9708770.
14. Rose B. Respiratory acidosis. Clinical Physiology of Acid-Base and Electrolytes Disorders 1984, 440-461. New York: McGraw-Hill, Rose B.
15. Faisy C, Mokline A, Sanchez O, Tadie JM, Fagon JY. Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation. Intensive Care Med 2010, 36:859-863. 10.1007/s00134-010-1795-7, 20217045.
16. Heming N, Faisy C, Urien S. Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients. Crit Care 2011, 15:R213. 10.1186/cc10448, 3334757, 21917139.
17. Wilson RF, Gibson D, Percinel AK, Ali MA, Baker G, LeBlanc LP, Lucas C. Severe alkalosis in critically ill surgical patients. Arch Surg 1972, 105:197-203. 10.1001/archsurg.1972.04180080051009, 5044546.
18. Hodgkin JE, Soeprono FF, Chan DM. Incidence of metabolic alkalemia in hospitalized patients. Crit Care Med 1980, 8:725-728. 10.1097/00003246-198012000-00005, 6778655.
19. Krintel JJ, Haxholdt OS, Berthelsen P, Brockner J. Carbon dioxide elimination after acetazolamide in patients with chronic obstructive pulmonary disease and metabolic alkalosis. Acta Anaesthesiol Scand 1983, 27:252-254. 10.1111/j.1399-6576.1983.tb01946.x, 6410668.
20. Berthelsen P. Cardiovascular performance and oxyhemoglobin dissociation after acetazolamide in metabolic alkalosis. Intensive Care Med 1982, 8:269-274. 10.1007/BF01716736, 6816846.
21. Holland AE, Wilson JW, Kotsimbos TC, Naughton MT. Metabolic alkalosis contributes to acute hypercapnic respiratory failure in adult cystic fibrosis. Chest 2003, 124:490-493. 10.1378/chest.124.2.490, 12907533.
22. Tobin MJ, Jubran A. Weaning from mechanical ventilation. Principles and Practice of Mechanical Ventilation 2006, 1185-1220. New York: McGraw-Hill, Tobin MJ, 2.
23. Khanna A, Kurtzman NA. Metabolic alkalosis. Respir Care 2001, 46:354-365.
24. Brimioulle S, Berre J, Dufaye P, Vincent JL, Degaute JP, Kahn RJ. Hydrochloric acid infusion for treatment of metabolic alkalosis associated with respiratory acidosis. Crit Care Med 1989, 17:232-236. 10.1097/00003246-198903000-00006, 2493354.
25. Berthelsen P, Gothgen I, Husum B, Jacobsen E. Oxygen uptake and carbon dioxide elimination after acetazolamide in the critically ill. Intensive Care Med 1985, 11:26-29.
26. Pastorekova S, Parkkila S, Pastorek J, Supuran CT. Carbonic anhydrases: current state of the art, therapeutic applications and future prospects. J Enzyme Inhib Med Chem 2004, 19:199-229. 10.1080/14756360410001689540, 15560002.
27. Temperini C, Cecchi A, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors. Comparison of chlorthalidone, indapamide, trichloromethiazide, and furosemide X-ray crystal structures in adducts with isozyme II, when several water molecules make the difference. Bioorg Med Chem 2009, 17:1214-1221. 10.1016/j.bmc.2008.12.023, 19119014.
28. Kiwull-Schone HF, Teppema LJ, Kiwull PJ. Low-dose acetazolamide does affect respiratory muscle function in spontaneously breathing anesthetized rabbits. Am J Respir Crit Care Med 2001, 163:478-483.
29. Sterling D, Alvarez BV, Casey JR. The extracellular component of a transport metabolon. Extracellular loop 4 of the human AE1 Cl-/HCO3- exchanger binds carbonic anhydrase IV. J Biol Chem 2002, 277:25239-25246. 10.1074/jbc.M202562200, 11994299.
30. Swenson ER. Carbonic anhydrase inhibitors and ventilation: a complex interplay of stimulation and suppression. Eur Respir J 1998, 12:1242-1247. 10.1183/09031936.98.12061242, 9877470.
31. Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008, 7:168-181. 10.1038/nrd2467, 18167490.
32. Schelegle ES, Green JF. An overview of the anatomy and physiology of slowly adapting pulmonary stretch receptors. Respir Physiol 2001, 125:17-31. 10.1016/S0034-5687(00)00202-4, 11240150.
33. Ravi K. Effect of carbon dioxide on the activity of slowly and rapidly adapting pulmonary stretch receptors in cats. J Auton Nerv Syst 1985, 12:267-277. 10.1016/0165-1838(85)90067-0, 2987336.
34. Sant'Ambrogio G, Miserocchi G, Mortola J. Transient responses of pulmonary stretch receptors in the dog to inhalation of carbon dioxide. Respir Physiol 1974, 22:191-197. 10.1016/0034-5687(74)90057-7, 4438854.
35. Matsumoto S, Okamura H, Suzuki K, Sugai N, Shimizu T. Inhibitory mechanism of CO2 inhalation on slowly adapting pulmonary stretch receptors in the anesthetized rabbit. J Pharmacol Exp Ther 1996, 279:402-409.
36. Teppema LJ, Dahan A. Acetazolamide and breathing. Does a clinical dose alter peripheral and central CO(2) sensitivity?. Am J Respir Crit Care Med 1999, 160:1592-1597.
37. Brechue WF, Koceja DM, Stager JM. Acetazolamide reduces peripheral afferent transmission in humans. Muscle Nerve 1997, 20:1541-1548. 10.1002/(SICI)1097-4598(199712)20:12<1541::AID-MUS9>3.0.CO;2-8, 9390667.
38. Swenson ER, Maren TH. A quantitative analysis of CO2 transport at rest and during maximal exercise. Respir Physiol 1978, 35:129-159. 10.1016/0034-5687(78)90018-X, 105387.
39. Cogan MG, Maddox DA, Warnock DG, Lin ET, Rector FC. Effect of acetazolamide on bicarbonate reabsorption in the proximal tubule of the rat. Am J Physiol 1979, 237:F447-454.
40. Lucci MS, Warnock DG, Rector FC. Carbonic anhydrase-dependent bicarbonate reabsorption in the rat proximal tubule. Am J Physiol 1979, 236:F58-65.
41. Moviat M, Pickkers P, van der Voort PH, van der Hoeven JG. Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients. Crit Care 2006, 10:R14. 10.1186/cc3970, 1550864, 16420662.
42. Kassamali R, Sica DA. Acetazolamide: a forgotten diuretic agent. Cardiol Rev 2011, 19:276-278. 10.1097/CRD.0b013e31822b4939, 21983315.
43. Posner JB, Plum F. The toxic effects of carbon dioxide and acetazolamide in hepatic encephalopathy. J Clin Invest 1960, 39:1246-1258. 10.1172/JCI104140, 441871, 14434376.
44. Uwai Y, Saito H, Hashimoto Y, Inui KI. Interaction and transport of thiazide diuretics, loop diuretics, and acetazolamide via rat renal organic anion transporter rOAT1. J Pharmacol Exp Ther 2000, 295:261-265.
45. Tzanakis N, Metzidaki G, Thermos K, Spyraki CH, Bouros D. Anaphylactic shock after a single oral intake of acetazolamide. Br J Ophthalmol 1998, 82:588. 1722600, 9713074.
46. Palmer BF, Alpern RJ. Metabolic alkalosis. J Am Soc Nephrol 1997, 8:1462-1469.
47. Vos PJ, Folgering HT, de Boo TM, Lemmens WJ, van Herwaarden CL. Effects of chlormadinone acetate, acetazolamide and oxygen on awake and asleep gas exchange in patients with chronic obstructive pulmonary disease (COPD). Eur Respir J 1994, 7:850-855.
48. Skatrud JB, Dempsey JA. Relative effectiveness of acetazolamide versus medroxyprogesterone acetate in correction of chronic carbon dioxide retention. Am Rev Respir Dis 1983, 127:405-412.
49. Mazur JE, Devlin JW, Peters MJ, Jankowski MA, Iannuzzi MC, Zarowitz BJ. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med 1999, 27:1257-1261. 10.1097/00003246-199907000-00004, 10446816.
50. Marik PE, Kussman BD, Lipman J, Kraus P. Acetazolamide in the treatment of metabolic alkalosis in critically ill patients. Heart Lung 1991, 20:455-459.
51. Dickinson GE, Myers ML, Goldbach M, Sibbald W. Acetazolamide in the treatment of ventilatory failure complicating acute metabolic alkalosis. Anesth Analg 1981, 60:608-610.
52. ClinicalTrials.gov homepage. (accessed on 19 march 2012)., http://clinicaltrials.gov/ct2/home